Current Impact and Application of Abuse-Deterrent Opioid Formulations in Clinical Practice

被引:1
|
作者
Lee, Ya-Han [1 ]
Brown, Daniel L. [2 ]
Chen, Hsiang-Yin [1 ,3 ]
机构
[1] Taipei Med Univ, Sch Pharm, Dept Clin Pharm, 250 Wu Hsin St, Taipei, Taiwan
[2] Calif Hlth Sci Univ, Coll Pharm, Clovis, CA USA
[3] Taipei Med Univ, Wan Fang Hosp, Dept Pharm, Taipei, Taiwan
关键词
Opioid abuse; abuse-deterrent formulations; ADF; post-marketing; FDA guidance; cost impact; abuse liking; physician attitude; generic abuse-deterrent formulation; clinical application; TAMPER-RESISTANT FORMULATIONS; EXTENDED-RELEASE HYDROCODONE; UNITED-STATES; CHRONIC PAIN; DOUBLE-BLIND; POSTOPERATIVE PAIN; SUBSTANCE-ABUSE; RISK-EVALUATION; NONMEDICAL USE; SINGLE-ENTITY;
D O I
暂无
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Abuse-deterrent formulations (ADFs) represent one novel strategy for curbing the potential of opioid abuse. Objective: We aim to compare and contrast the characteristics and applications of current abuse-deterrent opioid products in clinical practice. Methods: Literature searches were conducted in databases (Pubmed Medline, International Pharmaceutical Abstracts, Google Scholar) and official reports. Relevant data were screened and organized into: 1) epidemiology of opioid abuse, 2) mitigation strategies for reducing opioid abuse, 3) development of ADFs, and 4) clinical experience with these formulations. Results: Increasing trends of opioid abuse and misuse have been reported globally. There are 5 types of abuse-deterrent opioid products: physical chemical barrier, combined agonist/antagonist, sequestered aversive agent, prodrug, and novel delivery system. The advantages and disadvantages of the 5 options are discussed in this review. A total of 9 products with abuse-deterrent labels have been approved by the Food and Drug Administration (FDA). The rates of abuse, diversion, and overdose deaths of these new products are also discussed. A framework for collecting in-time data on the efficacy, benefit and risk ratio, and cost-effectiveness of these new products is suggested to facilitate their optimal use. Limitations: The present review did not utilize systematic review standards or meta-analytic techniques, given the large heterogeneity of data and outcomes reviewed. Conclusions: ADFs provide an option for inhibiting the abuse or misuse of oral opioid products by hindering extraction of the active ingredient, preventing alternative routes of administration, or causing aversion. Their relatively high costs, uncertain insurance policies, and limited data on pharmacoeconomics warrant collaborative monitoring and assessment by government agencies, pharmaceutical manufacturers, and data analysis services to define their therapeutic role in the future.
引用
收藏
页码:E1003 / E1023
页数:21
相关论文
共 50 条
  • [41] Is There Support for Abuse-Deterrent and Tamper-Resistant Opioid Formulations? Reply to Commentary
    Butler, Stephen F.
    JOURNAL OF PAIN, 2013, 14 (04): : 361 - 362
  • [42] IMPACT OF INTRODUCTION OF ABUSE-DETERRENT OXYCONTIN ON OPIOID OVERDOSE RATES
    Larochelle, Marc
    Zhang, Fang
    Ross-Degnan, Dennis
    Wharam, James F.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2014, 29 : S120 - S120
  • [43] Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain
    Hale, Martin E.
    Moe, Derek
    Bond, Mary
    Gasior, Maciej
    Malamut, Richard
    PAIN MANAGEMENT, 2016, 6 (05) : 497 - 508
  • [44] Non-Analgesic Effects of Opioids: Factors Relevant to Opioid Abuse and Abuse-Deterrent Formulations
    Pergolizzi, Joseph V., Jr.
    Raffa, Robert B.
    Pergolizzi, Jason S.
    Taylor, Robert, Jr.
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (37) : 6109 - 6115
  • [45] Abuse-Deterrent Formulations of Prescription Opioids Reply
    Cicero, Theodore J.
    Ellis, Matthew S.
    JAMA PSYCHIATRY, 2015, 72 (08) : 850 - 851
  • [46] Abuse-deterrent opioid analgesics: a guide for clinicians
    Carinci, Adam J.
    PAIN MANAGEMENT, 2020, 10 (01) : 55 - 62
  • [47] A New Abuse-Deterrent Opioid - Xtampza ER
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2016, 58 (1497): : 77 - 78
  • [48] Impact of Abuse-Deterrent OxyContin on Prescription Opioid Utilization in the United States
    Hwang, Catherine S.
    Chang, Hsien-Yen
    Alexander, G. Caleb
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 367 - 367
  • [49] PREVENTING PROVIDER MISINFORMATION AND IMPROVING OVERSIGHT OF ABUSE-DETERRENT OPIOID FORMULATIONS: A POLICY ANALYSIS
    Adams, Elizabeth T.
    ANNALS OF BEHAVIORAL MEDICINE, 2020, 54 : S57 - S57